Show simple item record

dc.contributor.authorIsraels, Sara J.
dc.contributor.authorMichelson, Alan D.
dc.date2022-08-11T08:10:11.000
dc.date.accessioned2022-08-23T16:58:35Z
dc.date.available2022-08-23T16:58:35Z
dc.date.issued2006-03-01
dc.date.submitted2012-04-25
dc.identifier.citationThromb Res. 2006;118(1):75-83. Epub 2005 Feb 1. doi: 10.1016/j.thromres.2004.12.016
dc.identifier.issn0049-3848 (Linking)
dc.identifier.doi10.1016/j.thromres.2004.12.016
dc.identifier.pmid16709476
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43402
dc.description.abstractPlatelets are essential for the maintenance of vascular integrity and control of bleeding at sites of injury, but they are also implicated in the progression of atherosclerotic lesions and arterial vascular thrombosis. The use of antiplatelet drugs for the primary and secondary prevention of cardiovascular and cerebrovascular thromboses in adult populations has been extensively evaluated, resulting in defined management strategies. Much less is known about the appropriate use of antiplatelet drugs (primarily aspirin) in infants and children for secondary prevention in ischemic stroke, for prevention of coronary artery thrombosis in Kawasaki disease, or for prevention of thromboembolism following surgery for congenital cardiac disease. Additional studies will be required to evaluate the relative benefits of aspirin and anticoagulants in these settings. A role for newer antiplatelet drugs in the management of pediatric arterial thrombosis is as yet unexplored.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16709476&dopt=Abstract">Link to article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.thromres.2004.12.016
dc.subjectCardiac Surgical Procedures
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectHumans
dc.subjectInfant
dc.subjectMucocutaneous Lymph Node Syndrome
dc.subjectPlatelet Activation
dc.subjectPlatelet Aggregation Inhibitors
dc.subjectStroke
dc.subjectThrombosis
dc.subjectHematology
dc.subjectOncology
dc.subjectPediatrics
dc.titleAntiplatelet therapy in children
dc.typeJournal Article
dc.source.journaltitleThrombosis research
dc.source.volume118
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_hematology/80
dc.identifier.contextkey2796570
html.description.abstract<p>Platelets are essential for the maintenance of vascular integrity and control of bleeding at sites of injury, but they are also implicated in the progression of atherosclerotic lesions and arterial vascular thrombosis. The use of antiplatelet drugs for the primary and secondary prevention of cardiovascular and cerebrovascular thromboses in adult populations has been extensively evaluated, resulting in defined management strategies. Much less is known about the appropriate use of antiplatelet drugs (primarily aspirin) in infants and children for secondary prevention in ischemic stroke, for prevention of coronary artery thrombosis in Kawasaki disease, or for prevention of thromboembolism following surgery for congenital cardiac disease. Additional studies will be required to evaluate the relative benefits of aspirin and anticoagulants in these settings. A role for newer antiplatelet drugs in the management of pediatric arterial thrombosis is as yet unexplored.</p>
dc.identifier.submissionpathpeds_hematology/80
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages75-83


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record